ABSCIENCES (EPA:AB) AB Science announces the publication of the masitinib positive pivotal Phase 3 trial in progressive forms of multiple sclerosis in the journal Neurology® Neuroimmunology & Neuroinflammation
Transparency directive : regulatory news
22/02/2022 18:08
ABSCIENCES's latest news
15/05/2024 20:16
13/03/2024 12:58
07/03/2024 15:20
06/03/2024 20:21
29/02/2024 11:49
26/02/2024 18:32
28/11/2023 19:22
27/11/2023 08:04
29/09/2023 19:49
18/09/2023 18:05
Other stories
16/05/2024 14:37
16/05/2024 14:33
16/05/2024 15:18
16/05/2024 18:14
16/05/2024 13:30
16/05/2024 09:50
16/05/2024 16:10
16/05/2024 17:50
16/05/2024 13:47
16/05/2024 16:20
16/05/2024 17:52
16/05/2024 17:30
16/05/2024 15:05
16/05/2024 17:29
16/05/2024 16:47
16/05/2024 13:10
16/05/2024 17:50
16/05/2024 16:20
16/05/2024 16:07
16/05/2024 12:22
16/05/2024 13:42
16/05/2024 08:00
16/05/2024 02:28
16/05/2024 13:15
16/05/2024 15:41
15/05/2024 23:24
16/05/2024 17:38
16/05/2024 12:53
16/05/2024 09:00
16/05/2024 13:27
16/05/2024 09:24
16/05/2024 18:19
15/05/2024 22:40
15/05/2024 11:19
16/05/2024 10:15
16/05/2024 07:01
16/05/2024 09:13
16/05/2024 12:07